NCT02528903View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 18, 2015

Primary Completion Date

January 26, 2016

Study Completion Date

January 26, 2016

Conditions
Healthy Volunteer
Interventions
DRUG

MHAB5553A

Single intravenous administration, at various doses, depending on the cohort

DRUG

Matching placebo

Single intravenous dose

Trial Locations (1)

G1P 0A2

inVentiv Health Clinique, Québec

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY